GAD2 and epilepsy: A small cohort study of ours showed that mixed immunotherapy including methylprednisolone therapy was effective in improving mood dysfunction in epilepsy patients presenting GAD65 autoantibodies rather than paraneoplastic autoantibodies (Hansen et al., 2016).